Advertisement

Cipla launches remdesivir for patients suffering from COVID-19

Mumbai-based company Cipla Pharmaceuticals has launched the drug remdesivir under the brand name Cipremi.

Cipla launches remdesivir for patients suffering from COVID-19
SHARES

Mumbai-based company Cipla Pharmaceuticals has launched remdesivir under the brand name Cipremi. Cipla plans on marketing and supplying the drug through both government and open market channels. Cipla stated that it will commercialize remdesivir through its own facilities and partnered sites.

The drug Cipremi has been approved for adult and paediatric patients who have been suspected or hospitalized because of contracting the coronavirus, particularly those who are on oxygen support.

The ICMR had earlier approved the use of remdesivir under Emergency Use Authorisation (EUA) treatment for patients with severe COVID-19 infection. The drug has been incorporated in the Ministry of Health's revised 'Clinical Management Protocols for COVID-19' as an "investigational therapy". The Drug Controller General of India (DCGI) has authorized approval for Cipla's drug for restricted urgent use across the country as part of the fastened approval process considering the urgent and unfulfilled medical need.

Cipla has stated the preliminary results from the ACTT-1 (Adaptive COVID-19 Treatment Trial 1) study1, which is a randomised clinical trial which was conducted with remdesivir on 1,063 patients, most of these patients were on oxygen support, across 60 centres in the US, Europe and Asia. The study has been able to showcase quicker clinical recovery in hospitalised patients as compared to placebo. Patients suffering from the coronavirus were either receiving high flow oxygen or non-invasive ventilation; some were on a mechanical ventilator. The mortality rate in the study was 7.1 per cent among given remdesivir and 11.9 per cent in those given placebo.

In other news, Glenmark pharmaceuticals under the brand name FabiFlu has introduced the antiviral drug Favipiravir to treat the coronavirus. Patients suffering from mild to moderate symptoms of the COVID-19 can use this drug to get themselves treated. The company has further said that it has further received permission from the Comptroller and Auditor General of India (DGCI) to manufacture and market the drug. Favipiravir is the first oral drug to treat the coronavirus, which has been approved. The drug will be available in the market at a rate of around ₹103 per tablet.

RELATED TOPICS
MumbaiLive would like to send you latest news updates